Cefditoren sodium
Based on 1 publication(s) in Google Scholar
Cefditoren sodium (ME 1206) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren sodium has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren sodium can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 95.56%
- CAS No.: 104146-53-4
- 화학식: C19H17N6NaO5S3
- 분자량:528.56
-
보관:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Cefditoren sodium
MoreAll Beta-lactamase Isoforms
More
Biological Activity
Cefditoren (sodium) shows good activity against pneumoniae, S. pyogenes, Staphylococcus aureus, H. influenzae and H. parainfluenzae, M. catarrhalis[1].
| Organism | MIC50 (mg/L) | MIC90 (mg/L) | susceptible (%) |
| Gram-positive organisms | |||
| Streptococcus pneumoniae (untyped)a | 0.015-0.25 | 0.12-1 | |
| PS | ≤0.008-0.03 | 0.015-0.25 | 99-100 |
| PI | 0.06-0.5 | 0.25-0.5 | 94-100 |
| PR | 0.25-1 | 0.5-2 | 7-100 |
| S. pyogenes | ≤0.008-0.03 | 0.015-0.03 | 100 |
| Staphylococcus aureus (MS) | 0.12-0.5 | 0.5-1 | 50-100 |
| Gram-negative organisms | |||
| Haemophilus | ≤0.008-≤0.03 | 0.015-0.13 | |
| influenzae (untyped)b | |||
| β-Lactamase + | ≤0.008-0.03 | 0.015-0.06 | 100 |
| β-Lactamase - | ≤0.008-0.03 | 0.015-0.06 | 100 |
| H. parainfluenzaeb | ≤0.03 | 0.06 | |
| Moraxella | 0.03-0.5 | 0.25-1 | 96 |
| catarrhalis (untyped)b | |||
| β-Lactamase + | ≤0.03-0.25 | 0.12-0.5 | 100 |
| β-Lactamase - | ≤0.008-0.03 | 0.015-0.06 | 100 |
b Including both β-lactamase-positive and -negative strains.
MIC50/90=mean minimum inhibitory concentrations required to inhibit the growth of 50% or 90% of bacterial strains; MS=susceptible to meticillin; PI=intermediate susceptibility to penicillin; PR=resistant to penicillin; PS=susceptible to penicillin.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Cefditoren (mg/kg) | C0 (μg/ml) | t1/2 (h) | AUClast (μg× h/ml) | Tlast (h) |
| 6.25 | 53.0 | 0.9 | 30.4 | 6 |
| 12.5 | 168.4 | 1.1 | 64.1 | 8 |
| 25 | 232.5 | 0.9 | 101.3 | 8 |
| 50 | 290.6 | 1.1 | 124.4 | 8 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 104146-53-4
-
Appearance Solid
-
분자량 528.56
-
화학식 C19H17N6NaO5S3
-
Color White to light yellow
-
SMILES
O=C(C1=C(/C=C\C2=C(N=CS2)C)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)([H])N1C3=O)O[Na]
-
Synonyms
ME 1206
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
용액&용해도
H2O : 100 mg/mL (189.19 mM; Need ultrasonic)
DMSO : 25 mg/mL (47.30 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
순도&문서
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wellington K, et al. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004;64(22):2597-618. [Content Brief]
[2]. Cafini F, et al. Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One. 2010 Aug 10;5(8):e12041. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.8919 mL | 9.4597 mL | 18.9193 mL | 47.2983 mL |
| 5 mM | 0.3784 mL | 1.8919 mL | 3.7839 mL | 9.4597 mL | |
| 10 mM | 0.1892 mL | 0.9460 mL | 1.8919 mL | 4.7298 mL | |
| 15 mM | 0.1261 mL | 0.6306 mL | 1.2613 mL | 3.1532 mL | |
| 20 mM | 0.0946 mL | 0.4730 mL | 0.9460 mL | 2.3649 mL | |
| 25 mM | 0.0757 mL | 0.3784 mL | 0.7568 mL | 1.8919 mL | |
| 30 mM | 0.0631 mL | 0.3153 mL | 0.6306 mL | 1.5766 mL | |
| 40 mM | 0.0473 mL | 0.2365 mL | 0.4730 mL | 1.1825 mL | |
| H2O | 50 mM | 0.0378 mL | 0.1892 mL | 0.3784 mL | 0.9460 mL |
| 60 mM | 0.0315 mL | 0.1577 mL | 0.3153 mL | 0.7883 mL | |
| 80 mM | 0.0236 mL | 0.1182 mL | 0.2365 mL | 0.5912 mL | |
| 100 mM | 0.0189 mL | 0.0946 mL | 0.1892 mL | 0.4730 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz